Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
Status:
Completed
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
Sodium glucose co-transporter 2 inhibitors (SGLT2i) proved their favorable outcomes in heart
failure. However, it is still unknown if their role extent into preventing heart failure,
especially after acute myocardial infarction. This study aimed at identifying if there is
such role for SGLT2i.